西班牙研究人員首次通過從人類心臟中提取的成熟細(xì)胞將脂肪組織的干細(xì)胞轉(zhuǎn)變成為心肌細(xì)胞,。換句話說，他們已經(jīng)重新編程了成熟的干細(xì)胞,，并能改善心臟病的治療效果。
目前,，利用干細(xì)胞治療心臟病非常普遍,。然而，沒有目標(biāo)心臟組織對于干細(xì)胞治療效果會有影響,。因此,，誘導(dǎo)細(xì)胞分化成心肌細(xì)胞是這類疾病治療上的最佳選擇之一。
研究人員從人類脂肪組織中分離出成熟的干細(xì)胞,，讓這些細(xì)胞暫時暴露于人類的心房細(xì)胞中,，隨后再對這些細(xì)胞重新進(jìn)行培養(yǎng)。經(jīng)過12天的培養(yǎng),，這些細(xì)胞向著心肌細(xì)胞的表型方向分化,，這可以通過以下方面得到證明：這些細(xì)胞從形態(tài)上發(fā)生了改變，表現(xiàn)為帶有纖維紋和分枝的雙核細(xì)胞,；免疫熒光檢查發(fā)現(xiàn),，它們帶有心臟特有的標(biāo)記；RT - PCR檢測證明,，這些細(xì)胞存在心肌基因,；它們有逆轉(zhuǎn)錄表達(dá)。這樣,，這些干細(xì)胞獲得了一個心臟的表型,。
未來可通過這項(xiàng)技術(shù)從患者身上直接提取細(xì)胞來再生心肌細(xì)胞。但是醫(yī)生們表示,，目前這項(xiàng)研究還處于初期階段,，要用于治療還有很長一段時間。
研究人員目前準(zhǔn)備了一種新的方法,，就是誘導(dǎo)細(xì)胞提取液使其變成靶細(xì)胞,，這樣就會獲得大量的分化細(xì)胞，這對治療很有必要,。下一步,，研究人員要通過動物驗(yàn)證這些分化細(xì)胞的功能。最后還要通過許多臨床試驗(yàn)來評價這項(xiàng)技術(shù)在人類中的可行性,。(生物谷Bioon.com)
生物谷推薦原文出處：
Cytotherapy DOI: 10.3109/14653240903548202
Human cardiac tissue induces transdifferentiation of adult stem cells towards cardiomyocytes
Macarena Perán?1,2*, Juan A. Marchal?2,3*, Elena López?2, Manuel Jiménez-Navarro?4, Houria Boulaiz?2,3, Fernando Rodríguez-Serrano?2,3, Esmeralda Carrillo?2,3, Gema Sánchez-Espin?4, Eduardo de Teresa?4, David Tosh?5 & Antonia Aranega?2,3
Department of Health Sciences, University of Jaén, Spain
Biopathology and Medicine Regenerative Institute (IBIMER), Granada, Spain
Department of Human Anatomy and Embryology, Faculty of Medicine, University of Granada, Spain
Heart Unit, Virgen de la Victoria, Clinical University Hospital, Málaga, Spain
Centre for Regenerative Medicine, Department of Biology and Biochemistry, University of Bath, UK
*These authors contributed equally to this work
Background aims. The goal was to induce the transdifferentiation (or conversion) of human adipose-derived stem cells to cardiomyocytes using an intracellular extract obtained from adult human heart tissue. Methods. Human adult stem cells from lipoaspirates were transiently permeabilized, exposed to human atrial extracts and allowed to recover in culture. Results. After 21 days, the cells acquired a cardiomyocyte phenotype, as demonstrated by morphologic changes (appearance of binucleate, striated cells and branching fibers), immunofluorescence detection of cardiac-specific markers (connexin-43, sarcomeric α-actinin, cardiac troponin I and T, and desmin) and the presence of cardiomyocyte-related genes analyzed by reverse transcription–polymerase chain reaction (cardiac myosin light chain 1, α-cardiac actin, cardiac troponin T and cardiac β-myosin). Conclusions. We have demonstrated for the first time that adult cardiomyocytes obtained from human donors retain the capacity to induce cardiomyocyte differentiation of mesenchymal stromal cells. The use of autologous extracts for reprogramming adult stem cells may have potential therapeutic implications for treating heart disease.
